He.utexas.edu

Yang, F., Friedrichs, W. E., Navarijo-Ashbaugh, A. L., deGraffenried, L. A., Bowman, B. H., and Coalson, J. J. Cell type-specific and inflammatory-induced expression of haptoglobin gene in lung, Lab Invest. 73: 433-40., 1995. Yang, F., Friedrichs, W. E., deGraffenried, L., Herbert, D. C., Weaker, F. J., Bowman, B. H., and Coalson, J. J. Cellular expression of ceruloplasmin in baboon and mouse lung during development and inflammation, Am J Respir Cell Mol Biol. 14: 161-9., 1996. Dechaud, H., Witz, C. A., Montoya-Rodriguez, I. A., Degraffenreid, L. A., and Schenken, R. S. Mesothelial cell-associated hyaluronic acid promotes adhesion of endometrial cells to mesothelium, Fertil Steril. 76: 1012-8., 2001. deGraffenried LA, Hilsenbeck SG, Fuqua SAW: Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol 82(1): 7-18, 2002. Grünwald, V., deGraffenried, L., Russel, D., Friedrichs, W. E., Ray, R. B., and Hidalgo, M. Inhibitors of mTOR Reverse Doxorubicin Resistance Conferred by PTEN Status in Prostate Cancer Cells. Cancer Res. 62 (21):, 2002. deGraffenried, L. A., Friedrichs, W. E., Fulcher, L., Fernandes, G., Silva, J. M., Peralba, J.-M., and Hidalgo, M. Eicosapentaenoic Acid Restores Tamoxifen Sensitivity in Breast Cancer Cells with High Akt Activity, Ann Oncol. 14: 1051-6, 2003. Malik, S. N., Siu, L. L., Rowinsky, E. K., deGraffenried, L., Hammond, L. A., Rizzo, J., Bacus, S., Brattain, M. G., Kreisberg, J. I., and Hidalgo, M. Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients, Clin Cancer Res. 9: 2478-2486, 2003. Peralba, J. M., deGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G., Rowinsky, E., Dukart, G., and Hidalgo, M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients, Clin Cancer Res 9(8):2887-92, 2003. deGraffenried, LA, Hopp TA, Valente AJ, Clark, RA, and Fuqua SAW. Regulation of the estrogen receptora minimal promoter by Sp1, USF-1 and ERa. Breast Cancer Res Treat, 85(2):111-120, 2004. deGraffenried, L. A., Friedrichs, W. E., Chandrasekar, B., Donzis, E., Silva, J., Hidalgo, M., Freeman, J. W., and Weiss, G. R. NF-kB Inhibition Markedly Enhances Sensitivity of Resistant Breast Cancer Tumor Cells to Tamoxifen, Ann Oncol. 15 (6):885-90, 2004. deGraffenried, LA, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, and Hidalgo M. Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity, Clin Cancer Res, 10(23):8059-8067, 2004. deGraffenried, L. A., Fulcher, L., Friedrichs, W. E., Grünwald, V., Ray, R. B., and Hidalgo, M. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3/Akt pathway, Ann Oncol. 15(10):1510-1516, 2004. Beeram B, Tan Q-T N, Tekmal RR, Russell D, Middleton A and deGraffenried LA. Akt-Induced Endocrine Therapy Resistance is Reversed by Inhibition of mTOR Signaling, Ann Oncol. 18:1323-1328, 2007. Silva J, Cavazos D, Donzis E, Friedrichs WE, Marciniak R, and deGraffenried LA. Akt-Induced Tamoxifen Resistance is Associated with Altered FKHR Regulation, Cancer Invest. 25:1-5, 2007. Troyer DA, Tang Y, Bedolla R, Adhvaryu SG, Thompson IM, Abboud-Werner, S Sun L-Z, Friedrichs WE, deGraffenried LA. Characterization of PacMetUT1, A Recently Isolated Human Prostate Cancer Cell Line, Prostate. 68(8):883-92, 2008. Silva JM, Ruparel S, Lin Y, Donzis E, Esquivel E, Tekmal RR and deGraffenried LA. A Novel Role for the ASK/JNK Pathway in Mediating Akt-Induced Endocrine Therapy Resistance. Mol Cancer Therapeutics, in press.

Source: http://he.utexas.edu/wp-content/uploads/2011/01/degrafpubs.pdf